Fidelity International’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Fidelity International’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-58,824	Closed	-$1.01M	–	538
2015 Q4	$1.01M	Sell	58,824 -99,865	-63%	-$2.38M	﹤0.01%	460
2015 Q3	$3.35M	Sell	158,689 -7,669	-5%	-$263K	0.01%	411
2015 Q2	$8.23M	Sell	166,358 -3,343	-2%	-$200K	0.03%	381
2015 Q1	$13.3M	Buy	169,701 +61,397	+57%	+$3.81M	0.04%	331
2014 Q4	$6.56M	Hold	108,304	–	–	0.02%	383
2014 Q3	$4.61M	Sell	108,304 -117,646	-52%	-$6.32M	0.02%	405
2014 Q2	$14M	Buy	225,950 +5,280	+2%	+$307K	0.05%	314
2014 Q1	$14.3M	Buy	220,670 +70,121	+47%	+$4.74M	0.05%	310
2013 Q4	$8.48M	Buy	150,549 +106,769	+244%	+$6M	0.03%	344
2013 Q3	$2.69M	Buy	+43,780	New	+$2.96M	0.01%	425

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fidelity International's OREX Position: Q1 2016 in Review

Fidelity International sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2016, closing a stake of 58,824 shares — an estimated $1.01M sold.

Fidelity International first reported a position in OREX in Q3 2013 and held it in 10 quarters. The position peaked at $14.3M in Q1 2014. 104 funds tracked by Wall St. Rank hold OREX as of Q1 2016.

Fidelity International reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
Fidelity International sold 58,824 Orexigen Therapeutics, Inc. shares in Q1 2016, an estimated $1.01M.
Fidelity International first reported a position in Orexigen Therapeutics, Inc. in Q3 2013 and held it in 10 quarters.
Fidelity International's Orexigen Therapeutics, Inc. position peaked at $14.3M in Q1 2014.
104 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2016.

Based on Fidelity International's 13F filing for Q1 2016, filed 16 May 2016.